TICKERNERD
Menu
ANNXANNXHealthcare · Biotechnology

ANNX Stock Forecast: Annexon, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.92
−5.31% on the day

The 10 Wall Street analysts covering Annexon, Inc. hold a median 12-month price target of $14 — +257.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$743.2M
Ticker Nerd rank
33 / 100
Median analyst target
$14
Analysts covering
10
Revenue$0.0
Operating income−$57.2M
Net income−$55.3M
Free cash flow−$48.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.0%
1M
−26.6%
YTD
−21.9%
1Y
+53.7%
From 52W high
−43.7%
From 52W low
+62.0%
$2.42
$6.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Annexon, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
66
Accruals
64
Growth
61
Size
48
Volatility
45
Issuance
42
Value
40
Revisions
28
Quality
20

Momentum (66): The shares have been drifting up relative to others.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Oct 25Jan 26Apr 26Jul 26ANNXHigh $27Median $14Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
8 Buy2 Hold0 Sell
Low $7Median $14High $27

The green dot is the last close — the median target sits +257.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026JP MorganMaintainsOverweight$10 → $14
13 Aug 2026CitizensUpgradeMarket Perform—
13 Aug 2026CitizensUpgradeMarket Perform—
21 July 2026CitizensInitiatesMarket Underperform$3.00
21 July 2026CitizensInitiatesMarket Underperform—
15 July 2026NeedhamMaintainsBuy$11 → $25
15 July 2026NeedhamMaintainsBuy—
12 May 2026Goldman SachsInitiatesNeutral—
20 Mar 2026Chardan CapitalMaintainsBuy—
23 Dec 2025Chardan CapitalInitiatesBuy—
2 Dec 2025Clear StreetInitiatesBuy—
19 Nov 2025Wells FargoMaintainsOverweight—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025NeedhamMaintainsBuy—
4 Mar 2025NeedhamReiteratesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Nov 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Annexon, Inc. returned +53.7% against +17.5% for the S&P 500, dividends included.

ANNX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26ANNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Annexon, Inc. (ANNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
3.7×

Cheaper than 27% of US stocks

EV / EBITDA
−2.7×

Cheaper than 74% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−105.3%

Higher than 13% of US stocks

Return on assets
−51.5%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Annexon, Inc. (ANNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Annexon, Inc. has a market value of $743.2M and an enterprise value of $562.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$202.7M.

  • Diluted earnings per share, trailing twelve months: $−1.16.

  • Free cash flow in the twelve months to 30 June 2026: −$193.2M.

  • Shares outstanding: 174.6M.

  • Trailing P/E: −2.9×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Annexon, Inc. employs 92 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ANNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANNXAnnexon, Inc.$743.2M
33
GYREGyre Therapeutics, Inc.$750.3M
41
NVCTNuvectis Pharma, Inc.$756.3M
67
MNPRMonopar Therapeutics, Inc.$736.8M
57
FDMT4D Molecular Therapeutics, Inc.$727.6M
52
ACHVAchieve Life Sciences, Inc.$724.8M
29
AURAAura Biosciences, Inc.$723.2M
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Annexon, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANNX news & analysis

Annexon to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Annexon, Inc. announced that its president and chief executive officer, Douglas Love, Esq., will participate in fireside chats at several investor conferences during September. The company is a biopharmaceutical firm developing targeted immunotherapies for neuroinflammatory diseases.

Why it matters — Annexon watchers would care because the CEO's participation in September investor conferences offers opportunities for the company to present its platform and engage with the investment community.

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 17 Aug 2026neutral

Annexon, Inc. announced that it granted inducement equity awards to three new non-executive employees under its 2022 Employment Inducement Award Plan. The awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This discloses new equity compensation for incoming employees, a routine corporate action that ANNX watchers may note for governance and hiring activity.

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Annexon, Inc. held its Q2 2026 earnings conference call, during which management discussed the company's financial results and business developments for the quarter.

Why it matters — Earnings calls provide investors with official updates on financial performance, operational progress, and management's outlook.

Annexon Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026neutral

Annexon expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy by adding an independent 24-month dual primary endpoint alongside the existing 15-month primary endpoint. The company remains confident in a planned Q4 assessment of the 15-month endpoint while seeking longer-term efficacy data for a potential product label.

Why it matters — A watcher would care because the trial expansion signals Annexon is positioning vonaprument for a more robust efficacy data package that could influence future regulatory labeling for the geographic atrophy treatment.

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

GlobeNewsWire · 12 Aug 2026positive

Annexon reported its second quarter 2026 financial results along with business updates and anticipated milestones. The company highlighted rapid, positive clinical outcomes in the GBS FORWARD study that reinforce the consistency and reproducibility of the tanruprubart treatment effect seen in Phase 3 and real-world evidence studies, with a BLA submission expected in Q4 2026.

Why it matters — The positive FORWARD study results and the expected Q4 2026 BLA submission signal meaningful clinical progress for tanruprubart, a key advancement in Annexon's pipeline.

FAQ

Frequently asked questions about ANNX stock

What is the ANNX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Annexon, Inc. have a median 12-month price target of $14, with estimates ranging from $7 to $27. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANNX stock a buy right now?

Of the 10 analysts covering Annexon, Inc., 8 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annexon, Inc. 33 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANNX?

As at 12 Sept 2026, Annexon, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (66 of 100).

Will ANNX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +257.1% from the last close, and Ticker Nerd's factor model ranks Annexon, Inc. 33 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANNX stock forecast for 2030?

No analyst covering Annexon, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $27 over the next 12 months.

How has ANNX stock performed over the past year?

Annexon, Inc. returned +53.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Annexon, Inc. do?

Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye.

What is the latest news on ANNX?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "Annexon to Participate in Upcoming September Investor Conferences". Annexon, Inc. announced that its president and chief executive officer, Douglas Love, Esq., will participate in fireside chats at several investor conferences during September. The company is a biopharmaceutical firm developing targeted immunotherapies for neuroinflammatory diseases.

Company

About Annexon, Inc.

Annexon Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target classical complement-driven inflammation in diseases of the body, brain, and eye. The company’s current pipeline includes investigational medicines for autoimmune, neurodegenerative, neuroimmune, and ophthalmic conditions, with programs designed to block C1q, the initiating molecule of the classical complement pathway. Its product candidates are being studied across areas such as Guillain-Barré syndrome, geographic atrophy, and other serious inflammatory disorders. Annexon’s work centers on complement biology, a mechanism involved in immune activation and tissue damage, giving the company a distinct position within precision immunotherapy research. Headquartered in Brisbane, California, Annexon serves the biotechnology and drug development market through clinical research, translational science, and late-stage therapeutic development.

CEO Mr. Douglas E. Love Esq., J.D. · 92 employees · United States · https://www.annexonbio.com